The dose-response relationship for tafenoquine-induced haemolysis in G6PD deficiency has not been well characterised (the entirety of the available data for the 300 mg dose comprises 3 heterozygous females with >40% enzyme activity, Rueangweerayut et al., 2017) but the risk is regarded as substantial, which is why the drug is restricted to patients with G6PD activity >70%. Here, G6PD is linked to G6PD deficiency.